Publications / Posters :: ContraFect Corporation (CFRX)

Publications / Posters

Technology

Home
Technology
Publications / Posters

Publications

Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus

Antimicrobial Agents & Chemotherapy, (2019) 63 (6) e02616-18

The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis

Antimicrobial Agents & Chemotherapy, (2019) 63 (4) e02291-18

Bacteriophage Lysin CF-301: a Potent Anti-Staphylococcal Biofilm Agent

Antimicrob. Agents Chemother (2017) 61 (7) e02666-16

Combination Therapy with Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus-Induced Murine Bacteremia

Journal of Infectious Diseases, (2014) 209 (9): 1469-1478.

Posters

Amurin Peptide App2-M1 Eradicates Stenotrophomonas maltophilia Biofilms Formed on Hemodialysis Catheters in the Setting of Human Infection

Amurin Peptide App2-M1 Eradicates Stenotrophomonas maltophilia Biofilms Formed on Hemodialysis Catheters in the Setting of Human Infection

Presented at ASM-ESCMID 2019, September 4, 2019

CF-301 and Daptomycin Treatment of Methicillin-Resistant Staphylococcus aureus Associated Experimental Osteomyelitis

CF-301 and Daptomycin Treatment of Methicillin-Resistant Staphylococcus aureus Associated Experimental Osteomyelitis

Presented at ASM 2019, June 23, 2019

Lysins Exhibit Potent Bactericidal Activity, Synergy and Antibiofilm Effects against Pseudomonas aeruginosa in Human Serum and Pulmonary Surfactant

Lysins Exhibit Potent Bactericidal Activity, Synergy and Antibiofilm Effects against Pseudomonas aeruginosa in Human Serum and Pulmonary Surfactant

Presented at ASM 2019, June 23, 2019

Bacteriophage Lysin CF-301 (Exebacase) in Addition to Daptomycin in a Simulated Endocardial Vegetation (SEV) PK/PD Model

Bacteriophage Lysin CF-301 (Exebacase) in Addition to Daptomycin in a Simulated Endocardial Vegetation (SEV) PK/PD Model

Presented at ASM 2019, June 23, 2019

PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models

PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models

Presented at ASM 2019, June 21, 2019

Pharmacodynamic Assessment of Lysin CF-301 (exebacase) in Addition to Daptomycin against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model

Pharmacodynamic Assessment of Lysin CF-301 (exebacase) in Addition to Daptomycin against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model

Presented at ASM 2019, June 21, 2019

Lysin GN123 Resensitizes Cabapenem-Resistant Pseudomonas aeruginosa to Imipenem

Lysin GN123 Resensitizes Cabapenem-Resistant Pseudomonas aeruginosa to Imipenem

Presented at ECCMID 2019, April 13, 2019

Lysin exebacase (CF-301) exhibits potent bactericidal activity in human synovial fluid against biofilm-forming Staph epidermidis isolates

Lysin exebacase (CF-301) exhibits potent bactericidal activity in human synovial fluid against biofilm-forming Staph epidermidis isolates

Presented at ECCMID 2019, April 13, 2019

Comparison of Lysin CF-301 (exebacase) Activity Against S. aureus Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates

Comparison of Lysin CF-301 (exebacase) Activity Against S. aureus Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates

Presented at ID Week 2018, October 5, 2018

CF-301 (Exebacase) Resensitizes Methicillin-Resistant Staphylococcus aureus (MRSA) to Penicillin Derivatives and First Generation Cephalosporins

CF-301 (Exebacase) Resensitizes Methicillin-Resistant Staphylococcus aureus (MRSA) to Penicillin Derivatives and First Generation Cephalosporins

Presented at ASM-ESCMID 2018, September 4, 2018

1
2
3
4
Next »